文献速递哮喘

按Arg16Gly β2基因型指导青少年哮喘用药的随机试验

Asthma prescribing according to Arg16Gly beta-2 genotype: a randomised trial in adolescents.
PubMed 文献 · Eur Respir J · 2021-08-19

在英格兰和苏格兰基层网络中纳入12–18岁使用吸入糖皮质激素的哮喘患者241例,随机接受基因型指导用药或标准指南照护,随访12个月,主要终点为PAQLQ变化。基因型指导组PAQLQ改善0.16(95%CI 0.00–0.31;P=0.049),低于预设临床阈值0.25;AA纯合型改善更大(0.42,95%CI 0.02–0.81;P=0.041)。

要点

  • 基因型指导用药较标准照护显著改善PAQLQ,但幅度低于临床阈值。
  • AA纯合型青少年从基因型指导用药中获益最大。
  • 这是首个显示基因型驱动哮喘用药改善临床结局的RCT。

核心结论

  • 基因型驱动的哮喘用药较标准照护显著改善PAQLQ,但改善幅度低于预设临床阈值0.25。
  • AA纯合型青少年从基因型指导用药中获益最大。

研究设计与样本

  • 在英格兰和苏格兰基层临床研究网络开展的实用性随机对照试验。
  • 纳入12–18岁使用吸入糖皮质激素的哮喘患者241例,平均年龄14.7±1.91岁,1:1随机分组。
  • 经过4周导入期后随访12个月,主要终点为PAQLQ变化。

主要发现

  • 基因型指导用药组PAQLQ较标准照护组改善0.16(95%CI 0.00–0.31;P=0.049)。
  • AA基因型患者中,个性化照护较标准照护PAQLQ改善0.42(95%CI 0.02–0.81;P=0.041)。
  • 哮喘控制、急性发作频率和医疗资源利用为次要结局。

关键数值与推荐

  • PAQLQ改善的预设临床阈值为0.25。
  • 总体PAQLQ改善0.16(95%CI 0.00–0.31;P=0.049)低于该阈值。
  • AA基因型PAQLQ改善0.42(95%CI 0.02–0.81;P=0.041)。

临床怎么用

  • 对12–18岁使用吸入糖皮质激素的哮喘患者,可考虑依据rs1042713 Arg16Gly基因型选择二线控制药物。
  • AA纯合型青少年可能从基因型指导用药中获益更多。

局限性

  • 总体PAQLQ改善低于预设临床阈值0.25。
  • 基因型指导用药在更年轻和更严重儿童哮喘中的作用尚需进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The A allele of rs1042713 (Arg16 amino acid) in the β2-adrenoreceptor is associated with poor response to long-acting β2-agonist (LABA) in young people with asthma. Our aim was to assess whether the prescribing of second-line controller with LABA or a leukotriene receptor antagonist according to Arg16Gly genotype would result in improvements in Pediatric Asthma-Related Quality of Life Questionnaire (PAQLQ). METHODS: We performed a pragmatic randomised controlled trial (RCT) via a primary care clinical research network covering England and Scotland. We enrolled participants aged 12-18 years with asthma taking inhaled corticosteroids. 241 participants (mean±sd age 14.7±1.91 years) were randomised (1:1) to receive personalised care (genotype directed prescribing) or standard guideline care. Following a 4-week run-in participants were followed for 12 months. The primary outcome measure was change in PAQLQ. Asthma control, asthma exacerbation frequency and healthcare utilisation were secondary outcomes. RESULTS: Genotype-directed prescribing resulted in an improvement in PAQLQ compared to standard care (0.16, 95% CI 0.00-0.31; p=0.049), although this improvement was below the pre-determined clinical threshold of 0.25. The AA genotype was associated with a larger improvement in PAQLQ with personalised versus standard care (0.42, 95% CI 0.02-0.81; p=0.041). CONCLUSION: This is the first RCT demonstrating that genotype-driven asthma prescribing is associated with a significant improvement in a clinical outcome compared to standard care. Adolescents with the AA homozygous genotype benefited most. The potential role of such β2-adrenoceptor genotype directed therapy in younger and more severe childhood asthma warrants further exploration.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Ruffles T, Jones CJ, Palmer C, et al. Asthma prescribing according to Arg16Gly beta-2 genotype: a randomised trial in adolescents. Eur Respir J. 2021. PMID: 33479111. doi:10.1183/13993003.04107-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。